What Are Olney’s Lesions?
In 1989, neuroscientist John Olney published research showing that high doses of NMDA receptor antagonists — specifically PCP and MK-801 — produced vacuolization (small holes) in certain neurons in the posterior cingulate and retrosplenial cortex of rats. These became known as “Olney’s Lesions.”
This research triggered significant concern about all NMDA antagonists, including DXM. The question: does DXM cause similar lesions in humans?
What the Research Shows
Animal Data
In rodents, DXM at high doses produces similar lesions to other NMDA antagonists. However, there are important caveats:
- The doses required are significantly higher on a mg/kg basis than typical human recreational doses
- Rats metabolize DXM differently than humans (higher proportion of certain metabolites)
- The specific affected brain regions and the relevance to human physiology remain debated
Non-Human Primates
Critically, studies of ketamine (a more potent NMDA antagonist) in non-human primates at clinical anesthetic doses have not demonstrated the same lesion pattern as in rodents. This suggests there may be a species difference that makes the rodent model less predictive for humans.
Human Data
There is no direct evidence of Olney’s Lesions in human brains from DXM or ketamine use at recreational doses. However, the absence of evidence is not evidence of absence — appropriate long-term neuroimaging studies have not been conducted in recreational DXM users.
What Does the Community Generally Believe?
Based on the available evidence, most harm reduction researchers believe that:
- Occasional 2nd plateau use in adults is unlikely to produce significant neurotoxic effects
- Very frequent high-dose use is genuinely concerning and should be avoided
- Long-term daily use or very frequent 3rd/4th plateau use carries real, if unquantified, neurological risk
- Frequency of use is probably more important than any single dose in terms of cumulative risk
Practical Harm Reduction Guidance
Minimize Frequency
The most evidence-based harm reduction advice is to minimize frequency. Tolerance and potential cumulative neurotoxicity both argue for long gaps between uses. Recommended minimum: 2 weeks. Preferred: monthly or less frequent.
Dose Conservatively
Higher doses produce greater NMDA antagonism. Staying at lower plateaus reduces both acute risk and any potential chronic neurotoxicity concern.
Protective Agents?
In animal models, certain antioxidants and GABA-A agonists (like diazepam) have been shown to reduce NMDA antagonist-induced neurotoxicity. Some DXM users use benzodiazepines for this reason. However, benzodiazepines carry their own significant risks and dependence potential — this is not a simple recommendation. Antioxidants (Vitamin C, etc.) are safer and may offer some protection, though human data is absent.
The Bottom Line
We genuinely don’t know the exact human risk profile for DXM-induced neuroplasticity changes at recreational doses. The precautionary principle argues for conservative, infrequent use. The available data does not suggest that occasional recreational use is unambiguously dangerous, but it also doesn’t provide reassurance for heavy, frequent use. Behave accordingly.